3yr
Real-World Data on Comparison of Lipid-Lowering Effects between Alirocumab and Evolocumab in Patients with Hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36440240/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Conclusions: The LDL-C lowering effects of alirocumab are similar to those of evolocumab in clinical practice.
Share
• Source: Acta Cardiologica Sinica
• Conclusions: “The LDL-C lowering effects of alirocumab are similar to those of evolocumab in clinical practice.”
• Taiwanese researchers compared characteristics, prescribed medications, plasma LDL-C levels, and percentages of reduction in LDL-C in 22 patients taking alirocumab vs. 22 patients taking evolocumab from February 2018 to September 2021.
• Compared with evolocumab users, alirocumab users more commonly received ezetimibe treatment (72.7% vs. 40.9%) and exhibited increased baseline LDL-C (165.6 ± 63.2 mg/dL vs. 130.8 ± 56.3 mg/dL). The plasma LDL-C levels in both arms at 6 months were comparable, as were decreases in LDL-C.
• Limitations of the current study include small sample size, which precluded detailed statistical analysis. Furthermore, the investigators did not monitor medication adherence, adverse reactions secondary to lipid-lowering therapy, and cardiac outcomes.